InspireMD to Participate in Upcoming November Investor Conferences
November 02, 2023 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery...
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23
November 01, 2023 14:19 ET
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th
October 30, 2023 09:21 ET
|
InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention...
InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients
October 12, 2023 07:00 ET
|
InspireMD, Inc.
Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid...
InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives
October 03, 2023 07:00 ET
|
InspireMD, Inc.
Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current...
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
August 31, 2023 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 07:00 ET
|
InspireMD, Inc.
- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on...
InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th
July 25, 2023 08:00 ET
|
InspireMD, Inc.
-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention...
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
June 26, 2023 08:00 ET
|
InspireMD, Inc.
Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform ...
InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 18, 2023 08:00 ET
|
InspireMD, Inc.
TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today...